Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs ...

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs ...

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

Cullinan shares data from T cell engager programs targeting autoimmune diseases - BioTuesdays

Cullinan Therapeutics (NASDAQ: CGEM) has reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager, in autoimmune diseases. According to Cullinan, CLN-978 demonstrated potential for immune reset, including remissions in systemic lupus erythematosus and rheumatoid arthritis. Initial velinotamig data show promising clinical activity, including complete r…